Suppr超能文献

导致甲状旁腺功能亢进-颌骨肿瘤综合征的副甲状旁腺素 L95P 错义突变体的核仁定位缺陷和显性干扰特性。

Defective nucleolar localization and dominant interfering properties of a parafibromin L95P missense mutant causing the hyperparathyroidism-jaw tumor syndrome.

机构信息

Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 8C-101, Bethesda, Maryland 20892, USA.

出版信息

Endocr Relat Cancer. 2010 May 18;17(2):513-24. doi: 10.1677/ERC-09-0272. Print 2010 Jun.

Abstract

The hyperparathyroidism-jaw tumor syndrome (HPT-JT) is a familial cancer syndrome that can result from germline inactivation of HRPT2/CDC73, a putative tumor suppressor gene that encodes parafibromin, a component of the transcriptional regulatory PAF1 complex with homology to the yeast protein Cdc73p. The vast majority of HRPT2/CDC73 germline mutations identified have been truncation or frameshift mutations, and loss of function due to missense mutation is rare. We report here a kindred with HPT-JT due to a germline L95P missense mutation in parafibromin. The mutant parafibromin was studied in vitro to understand the basis of its presumed loss-of-function. When transfected in cultured cells, the L95P mutant was expressed to a lower level than wild-type (wt) parafibromin, a difference that was not overcome by inhibition of the proteasomal degradation pathway. The L95P mutant parafibromin retained the ability to assemble with endogenous PAF1 complex components as evidenced by co-immunoprecipitation. Analysis of subcellular localization showed that the L95P mutant was markedly deficient in nucleolar localization compared to the wt, an impairment likely resulting from disruption of a putative nucleolar localization signal immediately upstream of the L95P mutation. Transfection of the L95P parafibromin mutant, but not the wt, enhanced cell cycle progression and increased cell survival in NIH-3T3 and HEK 293 cells, resulting apparently from dominant interference with endogenous parafibromin action. The simultaneous loss of nucleolar localization and acquisition of a growth stimulatory phenotype with the L95P mutation raise the possibility that parafibromin must interact with targets in the nucleolus to fully execute its tumor suppressor functions.

摘要

甲状旁腺功能亢进-颌骨肿瘤综合征(HPT-JT)是一种家族性癌症综合征,可由 HRPT2/CDC73 的种系失活引起,HRPT2/CDC73 是一种假定的肿瘤抑制基因,编码 parafibromin,它是转录调节 PAF1 复合物的一个组成部分,与酵母蛋白 Cdc73p 具有同源性。绝大多数鉴定的 HRPT2/CDC73 种系突变是截断或移码突变,由于错义突变导致功能丧失的情况很少见。我们在这里报告一个家族患有 HPT-JT,其原因是 parafibromin 中的种系 L95P 错义突变。体外研究了突变的 parafibromin,以了解其假定的失活功能的基础。当在培养的细胞中转染时,L95P 突变体的表达水平低于野生型(wt)parafibromin,这种差异不能通过抑制蛋白酶体降解途径来克服。L95P 突变体 parafibromin 仍然能够与内源性 PAF1 复合物成分组装,这一点可以通过共免疫沉淀证明。亚细胞定位分析表明,与 wt 相比,L95P 突变体在核仁中的定位明显不足,这种缺陷可能是由于 L95P 突变上游的假定核仁定位信号被破坏所致。转染 L95P 突变体 parafibromin,但不是 wt,增强了 NIH-3T3 和 HEK 293 细胞的细胞周期进程并增加了细胞存活,这显然是由于对内源性 parafibromin 作用的显性干扰。L95P 突变同时丧失核仁定位并获得生长刺激表型,这表明 parafibromin 必须与核仁中的靶标相互作用才能充分发挥其肿瘤抑制功能。

相似文献

3
Characterization of a new CDC73 missense mutation that impairs Parafibromin expression and nucleolar localization.
PLoS One. 2014 May 19;9(5):e97994. doi: 10.1371/journal.pone.0097994. eCollection 2014.
4
HRPT2, a tumor suppressor gene for hyperparathyroidism-jaw tumor syndrome.
Horm Metab Res. 2005 Jun;37(6):380-3. doi: 10.1055/s-2005-870150.
6
Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours.
Clin Endocrinol (Oxf). 2006 Mar;64(3):299-306. doi: 10.1111/j.1365-2265.2006.02460.x.
8
Analysis of aberrantly spliced HRPT2 transcripts and the resulting proteins in HPT-JT syndrome.
Mol Genet Metab. 2010 Aug;100(4):365-71. doi: 10.1016/j.ymgme.2010.03.017. Epub 2010 Mar 27.

引用本文的文献

1
Genotype-Phenotype Correlations in the Hyperparathyroidism-Jaw Tumor Syndrome.
J Clin Endocrinol Metab. 2025 Mar 17;110(4):931-939. doi: 10.1210/clinem/dgae909.
3
Phenotypic Profiling and Molecular Mechanisms in Hyperparathyroidism-jaw Tumor Syndrome.
J Clin Endocrinol Metab. 2023 Nov 17;108(12):3165-3177. doi: 10.1210/clinem/dgad368.
4
Molecular and Clinical Spectrum of Primary Hyperparathyroidism.
Endocr Rev. 2023 Sep 15;44(5):779-818. doi: 10.1210/endrev/bnad009.
5
Genetics and Epigenetics of Parathyroid Carcinoma.
Front Endocrinol (Lausanne). 2022 Feb 24;13:834362. doi: 10.3389/fendo.2022.834362. eCollection 2022.
6
Overview of the 2022 WHO Classification of Parathyroid Tumors.
Endocr Pathol. 2022 Mar;33(1):64-89. doi: 10.1007/s12022-022-09709-1. Epub 2022 Feb 17.
7
Cell-cell adhesion regulates Merlin/NF2 interaction with the PAF complex.
PLoS One. 2021 Aug 23;16(8):e0254697. doi: 10.1371/journal.pone.0254697. eCollection 2021.
8
Genomics and Epigenomics in Parathyroid Neoplasia: from Bench to Surgical Pathology Practice.
Endocr Pathol. 2021 Mar;32(1):17-34. doi: 10.1007/s12022-020-09656-9. Epub 2020 Dec 2.
9
Genotype of CDC73 germline mutation determines risk of parathyroid cancer.
Endocr Relat Cancer. 2020 Sep;27(9):483-494. doi: 10.1530/ERC-20-0149.
10
Intratumor heterogeneity in human parathyroid tumors.
Histol Histopathol. 2020 Nov;35(11):1213-1228. doi: 10.14670/HH-18-230. Epub 2020 May 29.

本文引用的文献

1
The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the c-myc proto-oncogene.
Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17420-5. doi: 10.1073/pnas.0710725105. Epub 2008 Nov 5.
2
The Pfam protein families database.
Nucleic Acids Res. 2008 Jan;36(Database issue):D281-8. doi: 10.1093/nar/gkm960. Epub 2007 Nov 26.
3
Nucleolar localization of parafibromin is mediated by three nucleolar localization signals.
FEBS Lett. 2007 Oct 30;581(26):5070-4. doi: 10.1016/j.febslet.2007.09.050. Epub 2007 Oct 1.
4
Clustal W and Clustal X version 2.0.
Bioinformatics. 2007 Nov 1;23(21):2947-8. doi: 10.1093/bioinformatics/btm404. Epub 2007 Sep 10.
7
Parafibromin inhibits cancer cell growth and causes G1 phase arrest.
Biochem Biophys Res Commun. 2006 Nov 10;350(1):17-24. doi: 10.1016/j.bbrc.2006.08.169. Epub 2006 Sep 7.
8
Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome.
Clin Endocrinol (Oxf). 2006 Jul;65(1):9-16. doi: 10.1111/j.1365-2265.2006.02534.x.
9
Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: implications for cancer surveillance.
J Clin Endocrinol Metab. 2006 Aug;91(8):2827-32. doi: 10.1210/jc.2005-1239. Epub 2006 May 23.
10
Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours.
Clin Endocrinol (Oxf). 2006 Mar;64(3):299-306. doi: 10.1111/j.1365-2265.2006.02460.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验